studi
undertaken
evalut
role
elisa
diagnosi
activ
tuberculosi
use
antigen
serum
level
antippd
igg
ychain
specif
antibodi
measur
follow
group
patient
case
epidem
influenza
clinic
case
pneumopatia
determin
mean
laboratori
assess
viru
isol
indirect
immunofluoresc
specif
serolog
test
type
influenza
viru
incrimin
case
case
incrimin
associ
influenza
viru
parainfluenza
virus
adenovirus
coronavirus
sr
viru
small
number
case
children
sever
respiratori
diseas
examin
tracheabronch
aspir
posit
bacteria
fungi
associ
virusbacteria
found
case
confirm
graviti
evolut
prognost
studi
particular
refer
etiolog
sever
respiratori
diseas
requir
enabl
thu
real
evalu
infecti
morbid
adequ
approach
treatment
mean
elisa
valu
patient
significantli
higher
compar
control
p
ool
total
mb
strain
isol
differ
mammalian
speci
bovin
felin
cat
one
camelida
llama
seal
mb
isol
form
tb
patient
includ
studi
bp
probe
hybrid
uniqu
kg
restrict
fragment
mb
strain
either
one
fragment
differ
posit
ohn
fragment
strainsisol
bovin
llama
cat
tb
patient
restrict
fragment
pattern
four
mb
strain
seal
ident
clearli
differ
remain
mb
strain
use
probe
allow
us
confirm
transmiss
infect
herd
mb
isol
cow
ident
differ
isol
found
region
argentin
mb
strain
present
one
copi
limit
use
element
epidemiolog
surveil
enzymelink
immunoassay
eia
wide
use
clinic
practic
antimycobacteri
antibodi
detect
still
develop
eiavari
base
new
specif
micobacteriaderiv
antigen
never
stop
antigen
preparat
bovi
bcg
russia
cell
wall
purifi
triton
extract
subsequ
auton
sediment
ether
treatment
complex
antigen
name
triton
fraction
tf
contain
three
serolog
activ
antigen
determin
ident
triton
fraction
separ
virul
micobacteri
strain
bovi
humanu
provid
us
opportun
use
eia
test
system
specif
antibodi
detect
lung
tuberculosi
patient
sera
serum
sampl
delut
sensit
method
rang
depend
form
activ
lung
tuberculosi
process
dilut
sera
group
healthi
blood
donor
gave
specif
test
falseposit
result
obtain
test
dilut
sera
nontuberculosi
lung
patient
method
describ
use
confirm
diagnosi
tuberculosi
clinic
practic
well
high
risk
group
detect
mass
survey
epidem
centr
schaaf
h
beyer
n
nel
e
conclus
cultur
rate
mtb
significantli
higher
spring
season
support
trend
children
tbm
specul
tb
infect
occur
winter
present
diseas
spring
tabl
drug
involv
mostli
h
multidrug
resist
drug
mdr
remain
stabl
sinc
mdr
due
h
resist
tabl
risk
factor
sdr
mdr
statu
foreign
born
previou
treatment
great
urban
popul
germani
found
increas
rel
high
rate
mtb
resist
sinc
studi
conduct
activ
pulmonari
b
case
match
control
subject
patient
hat
sputum
posit
acid
fast
bacilli
subject
full
clinic
examin
includ
chest
xray
blood
sampl
taken
admiss
one
two
month
follow
start
anti
tb
therapi
routin
analysi
well
serum
ada
igg
result
studi
reveal
admiss
mean
ada
level
k
ul
significantli
higher
control
group
ul
valu
ada
admiss
significantli
higher
one
two
month
treatment
impli
import
ada
predictor
success
treatment
serum
igg
present
significantli
higher
valu
month
treatment
level
admiss
cutoff
valu
unit
chosen
patient
found
posit
igg
admiss
figur
increas
month
treatment
may
signifi
role
igg
long
term
follow
predictor
immunolog
respons
tb
infect
correl
found
either
ada
igg
type
extent
radiolog
find
extent
tuberculin
activ
